Kazia Therapeutics Ltd ADR
KZIAHealthcare|Biotechnology|AU
$7.18
+0.18 (+2.57%)
Tangible Book / Share
$14.53
Cash / Share
$22.24
Financials
Financial Snapshot
Market Cap
$11.6M
Enterprise Value
-$52.4M
Revenue (TTM)
$2.5M
Net Income (TTM)
-$50.7M
Cash & Investments
$69.4M
Net Cash
$69.3M
Free Cash Flow (TTM)
-$16.5M
Operating CF (TTM)
-$20.7M
Debt/Equity
0.00
Cash Runway & Burn Rate
Cash on Hand
$69.4M
Quarterly Burn
$5.2M
Monthly Burn
$1.7M
Est. Runway
~13.4 quarters
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Investments | $33.5M | $14.5M | $6.0M | $5.5M | $8.8M | $27.6M | $7.4M | $5.2M | $1.7M | $4.3M | $69.4M | |
| Operating Cash Flow | -$12.0M | -$11.4M | -$8.7M | -$6.7M | -$8.8M | -$9.1M | -$22.8M | -$15.2M | -$9.6M | -$13.3M | -$20.7M | |
| Free Cash Flow | -$12.5M | -$11.4M | -$8.7M | -$6.7M | -$8.8M | -$9.1M | -$22.8M | -$15.2M | -$9.6M | -$13.3M | -$16.5M | |
| Capital Expenditure | -$525.0K | -$11.6K | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $4.1M | |
| Financing Cash Flow | $782.0K | -$17.7K | $0.00 | $3.8M | $12.1M | $28.1M | $3.7M | $13.0M | $6.0M | $16.0M | $84.6M |
R&D Spending
R&D (TTM)
$25.2M
R&D Intensity
998.4%
R&D Growth vs Prior
+243.9%
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $4.1M | $8.8M | $13.1K | $1.6K | $988.1K | $15.2M | $10.0K | $555.00 | $2.3M | $42.0K | $2.5M | |
| R&D Expense | $9.9M | $11.1M | $9.8M | $6.5M | $9.5M | $14.5M | $20.2M | $15.6M | $17.4M | $7.3M | $25.2M | |
| R&D % of Revenue | 243.0% | 126.7% | 74565.2% | 413801.9% | 960.9% | 95.8% | 201690.0% | 2804336.9% | 753.0% | 17442.9% | 998.4% | |
| SG&A | $5.8M | $8.5M | $5.6M | $3.8M | $3.7M | $7.0M | $5.2M | $8.6M | $13.6M | $8.7M | $26.0M |
Income Statement
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $4.1M | $8.8M | $13.1K | $1.6K | $988.1K | $15.2M | $10.0K | $555.00 | $2.3M | $42.0K | $2.5M | |
| Cost of Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Gross Profit | $4.1M | $8.8M | $13.1K | $1.6K | $988.1K | $15.2M | $10.0K | $555.00 | $2.3M | $42.0K | $2.5M | |
| R&D | $9.9M | $11.1M | $9.8M | $6.5M | $9.5M | $14.5M | $20.2M | $15.6M | $17.4M | $7.3M | $25.2M | |
| SG&A | $5.8M | $8.5M | $5.6M | $3.8M | $3.7M | $7.0M | $5.2M | $8.6M | $13.6M | $8.7M | $26.0M | |
| Operating Income | -$12.8M | -$10.9M | -$12.5M | -$8.4M | -$12.2M | -$6.4M | -$25.4M | -$24.1M | -$28.5M | -$14.2M | -$47.1M | |
| Interest Expense | $0.00 | $0.00 | $0.00 | $2.2M | $0.00 | $0.00 | $2.1K | $0.00 | $0.00 | $0.00 | $0.00 | |
| Pretax Income | -$12.2M | -$10.9M | -$6.3M | -$10.6M | -$12.8M | -$8.9M | -$25.4M | -$20.7M | -$27.0M | -$22.4M | -$52.9M | |
| Net Income | -$12.1M | -$10.7M | -$6.0M | -$10.3M | -$12.5M | -$8.4M | -$25.0M | -$20.5M | -$26.8M | -$20.7M | -$50.7M | |
| EPS (Diluted) | -135.20 | -109.30 | -59.80 | -85.60 | -80.00 | -35.80 | -95.00 | -55.00 | -55.00 | -18.90 | -47.70 | |
| EBITDA | -$11.7M | -$9.4M | -$13.0M | -$7.7M | -$11.1M | -$5.1M | -$23.5M | -$22.3M | -$26.6M | -$13.3M | -$45.7M | |
| Shares Out. (M) | 0.09 | 0.10 | 0.10 | 0.12 | 0.15 | 0.24 | 0.27 | 0.37 | 0.48 | 1.10 | 3.12 |
Balance Sheet
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $33.5M | $14.5M | $6.0M | $5.4M | $8.8M | $27.6M | $7.4M | $5.2M | $1.7M | $4.3M | $69.4M | |
| Short-Term Investments | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Total Current Assets | $34.1M | $19.5M | $9.3M | $7.5M | $10.7M | $29.4M | $9.4M | $10.8M | $6.1M | $4.9M | $69.9M | |
| Total Assets | $35.5M | $35.9M | $28.2M | $21.2M | $23.1M | $58.1M | $35.9M | $28.1M | $21.6M | $6.1M | $71.0M | |
| Total Current Liabilities | $1.4M | $5.4M | $3.9M | $2.2M | $5.1M | $8.3M | $6.7M | $7.6M | $25.8M | $14.1M | $24.3M | |
| Long-Term Debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Total Liabilities | $1.6M | $10.6M | $8.9M | $7.0M | $8.9M | $20.2M | $17.6M | $16.0M | $31.6M | $14.4M | $24.6M | |
| Stockholders' Equity | $33.9M | $25.3M | $19.2M | $14.2M | $14.1M | $37.9M | $18.3M | $12.1M | -$10.0M | -$8.3M | $46.4M | |
| Retained Earnings | -$160.5M | -$171.0M | -$14.6M | -$24.9M | -$36.2M | -$44.2M | -$68.6M | -$89.1M | -$115.1M | -$134.8M | -$145.5M |
Cash Flow Statement
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$12.0M | -$11.4M | -$8.7M | -$6.7M | -$8.8M | -$9.1M | -$22.8M | -$15.2M | -$9.6M | -$13.3M | -$20.7M | |
| Capital Expenditure | -$525.0K | -$11.6K | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $4.1M | |
| Free Cash Flow | -$12.5M | -$11.4M | -$8.7M | -$6.7M | -$8.8M | -$9.1M | -$22.8M | -$15.2M | -$9.6M | -$13.3M | -$16.5M | |
| Investing Cash Flow | -$522.0K | -$7.1M | $150.0K | $2.4M | $0.00 | $0.00 | -$2.4M | $0.00 | $0.00 | $0.00 | $0.00 | |
| Financing Cash Flow | $782.0K | -$17.7K | $0.00 | $3.8M | $12.1M | $28.1M | $3.7M | $13.0M | $6.0M | $16.0M | $84.6M | |
| Issuance of Stock | $853.0K | $0.00 | $0.00 | $3.8M | $12.1M | $28.1M | $3.7M | $13.0M | $5.6M | $14.8M | $59.6M | |
| Repurchase of Stock | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Net Debt Issuance | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $405.0K | $0.00 | -$522.5K | |
| Stock Based Comp. | $372.0K | $517.0K | $165.0K | $246.0K | $262.0K | $637.0K | $1.7M | $1.2M | $533.0K | $653.0K | $328.7K | |
| Net Change in Cash | -$10.9M | -$19.0M | -$8.5M | -$522.0K | $3.3M | $18.8M | -$20.2M | -$2.1M | -$3.6M | $2.7M | $66.0M |
Dilution Tracker
Shares outstanding grew 618.5% over 5 years — significant dilution
Shares Outstanding
2M
5-Year Share Growth
+618.5%
Stock Issuance (TTM)
$59.6M
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Shares Out. (M) | 0.09 | 0.10 | 0.10 | 0.12 | 0.15 | 0.24 | 0.27 | 0.37 | 0.48 | 1.10 | 3.12 | |
| Change vs Prior % | — | 9.5% | 3.4% | 18.9% | 27.0% | 54.4% | 12.6% | 39.1% | 30.1% | 128.4% | 184.9% | |
| Stock Issuance | $853.0K | $0.00 | $0.00 | $3.8M | $12.1M | $28.1M | $3.7M | $13.0M | $5.6M | $14.8M | $59.6M | |
| Stock Repurchase | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Stock Based Comp. | $372.0K | $517.0K | $165.0K | $246.0K | $262.0K | $637.0K | $1.7M | $1.2M | $533.0K | $653.0K | $328.7K |
Margins & Profitability
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| Operating Margin % | -313.7% | -123.5% | -95262.4% | -535463.3% | -1234.3% | -42.0% | -253990.0% | -4346661.1% | -1233.2% | -33850.0% | -1866.7% | |
| Net Margin % | -296.3% | -121.4% | -46071.1% | -656230.0% | -1261.7% | -55.5% | -250140.0% | -3687419.8% | -1160.2% | -49290.5% | -2008.8% | |
| EBITDA Margin % | -287.9% | -107.4% | -99336.3% | -492715.7% | -1124.4% | -33.7% | -235150.0% | -4013968.8% | -1152.2% | -31626.2% | -1811.2% | |
| FCF Margin % | -307.2% | -130.2% | -66074.2% | -429009.6% | -891.6% | -60.0% | -227620.0% | -2730810.8% | -415.1% | -31614.3% | -655.2% | |
| ROE % | -35.5% | -42.1% | -31.4% | -72.3% | -88.3% | -22.2% | -136.9% | -169.8% | 267.3% | 249.4% | -116.9% | |
| ROA % | -34.0% | -29.7% | -21.4% | -48.5% | -54.1% | -14.5% | -69.7% | -72.9% | -124.1% | -341.6% | -31.4% | |
| ROIC % | -37.5% | -34.9% | -48.8% | -42.9% | -66.2% | -12.1% | -80.7% | -106.7% | 787.5% | 172.6% | -36.2% | |
| R&D / Revenue % | 243.0% | 126.7% | 74565.2% | 413801.9% | 960.9% | 95.8% | 201690.0% | 2804336.9% | 753.0% | 17442.9% | 998.4% |
Growth (Year over Year)
Fiscal years. Rising share count growth means dilution.
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 4474.2% | 115.9% | -99.9% | -88.1% | 63038.0% | 1436.6% | -99.9% | -94.5% | 415755.9% | -98.2% | |
| Gross Profit | 4474.2% | 115.9% | -99.9% | -88.1% | 63038.0% | 1436.6% | -99.9% | -94.5% | 415755.9% | -98.2% | |
| Operating Income | -56.9% | 15.0% | -15.1% | 32.9% | -45.5% | 47.7% | -298.4% | 5.0% | -18.0% | 50.0% | |
| Net Income | -69.0% | 11.5% | 43.4% | -70.1% | -21.4% | 32.5% | -197.1% | 18.2% | -30.8% | 22.7% | |
| EPS (Diluted) | 5.8% | 19.2% | 45.3% | -43.1% | 6.5% | 55.3% | -165.4% | 42.1% | 0.0% | 65.6% | |
| Operating Cash Flow | -108.0% | 4.6% | 24.3% | 22.5% | -31.2% | -3.4% | -149.8% | 33.4% | 36.8% | -38.6% | |
| Free Cash Flow | -113.5% | 8.5% | 24.3% | 22.5% | -31.2% | -3.4% | -149.8% | 33.4% | 36.8% | -38.6% | |
| R&D Expense | 66.7% | 12.6% | -12.2% | -33.7% | 46.6% | 53.2% | 38.7% | -22.8% | 11.7% | -57.8% | |
| SG&A Expense | 49.9% | 48.0% | -34.4% | -32.4% | -2.5% | 90.3% | -25.4% | 63.8% | 58.0% | -35.7% | |
| Total Assets | -23.0% | 1.1% | -21.5% | -24.8% | 8.9% | 151.9% | -38.2% | -21.7% | -23.1% | -71.9% | |
| Book Value / Share | -57.3% | -31.8% | -26.6% | -38.0% | -21.5% | 73.6% | -57.1% | -52.6% | -163.9% | 63.7% | |
| Debt | 0.0% | 0.0% | 740.0% | -100.0% | 0.0% | 0.0% | 0.0% | -2.4% | -64.7% | -37.5% | |
| Diluted Shares | 79.3% | 9.5% | 3.4% | 18.9% | 27.0% | 54.4% | 12.6% | 39.1% | 30.1% | 128.4% |
Valuation
P/E (TTM)At Loss
P/S855.94
10Y Low / Med / High2.60 / 248.45 / 57807.50
P/B0.70
10Y Low / Med / High0.90 / 2.65 / 4.41
EV/EBITDA2.89
EV/Revenue-2659.65
10Y Low / Med / High0.95 / 154.43 / 51600.30
P/FCFAt Loss
Intrinsic Value Models (per share)
Tangible Book / Share
$14.53
Net Current Assets / Share
$27.96
Graham Net-Net
$14.42
Cash / Share
$22.24
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio | -3.72 | -2.14 | -3.34 | -2.20 | -3.07 | -18.36 | -3.20 | -1.58 | -0.30 | -0.50 | -1.01 | |
| P/S Ratio | 11.01 | 2.60 | 1539.11 | 14421.39 | 37.88 | 10.19 | 8060.35 | 57807.50 | 3.38 | 248.45 | 855.94 | |
| P/B Ratio | 1.32 | 0.90 | 1.05 | 1.59 | 2.65 | 4.09 | 4.41 | 2.66 | -0.78 | -1.26 | 0.70 | |
| EV/EBITDA | -0.97 | -0.89 | -1.10 | -2.22 | -2.58 | -24.87 | -3.19 | -1.29 | -0.26 | -0.49 | 2.89 | |
| EV/Revenue | 2.79 | 0.95 | 1091.14 | 10949.19 | 29.01 | 8.37 | 7508.35 | 51600.30 | 2.94 | 154.43 | -2659.65 |
Analyst Estimates & Quality
Altman Z-Score
-2.54
Distress
Piotroski F-Score
2
Weak
Forward Estimates (consensus)
| Metric | FY2027 | FY2028 | FY2029 |
|---|---|---|---|
| Revenue | $1.0M | $1.1M | $1.2M |
| Net Income | -$987.7K | -$1.5M | -$1.7M |
| EPS | $-0.90 | $-1.41 | $-1.58 |
| # Analysts (EPS) | 2 | 1 | 1 |
Revenue Segments
By Product
| Segment | 2021 | 2024 | 2025 |
|---|---|---|---|
| Licensing Revenue | $15.2M | $2.3M | — |
By Geography
| Segment | 2021 | 2025 |
|---|---|---|
| CHINA | $10.0M | — |
| Swedan | $5.2M | — |
| ISRAEL | — | $42.0K |